|
[1]
|
A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing
British Journal of Clinical Pharmacology,
2020
DOI:10.1111/bcp.14312
|
|
|
|
|
[2]
|
A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing
British Journal of Clinical Pharmacology,
2020
DOI:10.1111/bcp.14312
|
|
|
|
|
[3]
|
Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
Journal of Medical Economics,
2019
DOI:10.1080/13696998.2019.1606813
|
|
|
|
|
[4]
|
Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?
Journal of Clinical Medicine,
2019
DOI:10.3390/jcm8081237
|
|
|
|
|
[5]
|
Unmet needs in the treatment of Rheumatoid Arthritis. An observational study and a real-life experience from a single university center.
Seminars in Arthritis and Rheumatism,
2018
DOI:10.1016/j.semarthrit.2018.06.003
|
|
|
|
|
[6]
|
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis
Medicine,
2018
DOI:10.1097/MD.0000000000011609
|
|
|
|
|
[7]
|
The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial
Clinical and Experimental Immunology,
2018
DOI:10.1111/cei.13061
|
|
|
|
|
[8]
|
Sonodelivery Facilitates Sustained Luciferase Expression from an Episomal Vector in Skeletal Muscle
Materials,
2015
DOI:10.3390/ma8074608
|
|
|
|